Please assess the completion status of the following clinical trial:

Trial Title: A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have a confirmed diagnosis of type 1 Gaucher disease with a documented gene mutation;~* Clinically stable and on a stable dose of ERT for at least 2 years before study entry, with no changes to dose level or regimen in the last 6 months;~* Willing to stop ERT for the duration of the study;~* Male or female between the ages of 18 to 65 inclusive;~* All subjects of reproductive potential are required to practice an acceptable method of contraception;~* All subjects must have a body mass index of less than 30; and~* Provide written informed consent to participate in the study.~Exclusion Criteria:~* A clinically significant disease, severe complications from Gaucher disease, or serious intercurrent illness that may preclude participation in the study in the opinion of the Investigator;~* During the screening/wash out period, any clinically significant findings, based on physical exam, medical history review, lab assessment, vital sign assessment and/or other significant finding which would compromise the safety of the subject, or preclude the subject from completing the study as deemed by the Investigator;~* Partial or total splenectomy;~* History of pulmonary hypertension or Gaucher-related lung disease;~* History of allergy or sensitivity to the study drug or any excipients, including any prior serious allergic reaction to iminosugars;~* Screening or Day 1 (before dosing) 12-lead ECG demonstration QTc \>450 msec in males or \>470 in females;~* Pregnant or breast-feeding;~* Current/recent drug or alcohol abuse within the past 12 months;~* Treatment with any investigational product, including investigational forms of ERT, in the 90 days before study entry;~* Treatment in the previous 90 days with any drug known to have a well-defined potential for toxicity to a major organ;~* Presence or sequelae of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs; or~* Subject is otherwise unsuitable for the study in the opinion of the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AT2101 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).